Back to WELLINGTON MANAGEMENT GROUP LLP WELLINGTON MANAGEMENT GROUP LLP

PTGXPTGX
8 quarters

Position history for WELLINGTON MANAGEMENT GROUP LLPWELLINGTON MANAGEMENT GROUP LLP's holdings in Protagonist Therapeutics

Yes. Wellington Management Group holds 3,416,781 shares of PTGX (Protagonist Therapeutics), worth $418.8M, as of its Q2 2026 13F filing. It reduced the position by 182,863 shares (-5.1%) from Q1 2026. Wellington Management Group has held PTGX since Q3 2024, across 8 quarterly 13F filings. PTGX is 0.1% of Wellington Management Group's reported 13F portfolio.

Current Value

$418.8M

Current Shares

3.4M

Total Value Change

+$417.5M

Total Shares Change

+3.4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
3.4M
-5.1%
$418.8M0.1%$122.58
0
2026-Q1
Increased
3.6M
+13.5%
$379.4M0.1%$105.40
35
2025-Q4
Increased
3.2M
+66.2%
$277M0.0%$87.34
45
2025-Q3
Increased
1.9M
+83.9%
$126.8M0.0%$66.43
47
2025-Q2
Increased
1M
+5.1%
$57.4M0.0%$55.27
31
2025-Q1
Increased
987,370
+5.0%
$47.7M0.0%$48.36
31
2024-Q4
Increased
940,077
+3025.4%
$36.3M0.0%$38.60
47
2024-Q3
New
30,079
-
$1.4M0.0%$45.00
35

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used